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Abstract
This study reported the efficacy of short course corticosteroids and convalescent plasma (CP) 
transfusion in treating five patients with severe COVID-19 disease. Five adults (mean age: 
70 ± 9 years) with laboratory-confirmed COVID-19 and severe hypoxemia (PaO2/FiO2 [P/F] 
<100) requiring invasive mechanical ventilation received 5-days methylprednisolone (40 mg 
intravenously every 12 hours) and subsequent CP transfusion (250-400 ml). Compared with 
the baseline, P/F ratios increased by 46% and by 28% after short course corticosteroids and 
CP transfusion. Four patients survived. Short course corticosteroids and CP transfusion may 
improve hypoxemia in patients with severe COVID-19 disease. 
Introduction
COVID-19 is an enveloped single stranded RNA virus, Severe Acute Respiratory Syn-
drome Coronavirus 2 (SARS-CoV-2) that was first reported in Wuhan, China in Decem-
ber 2019. Since then COVID-19 disease has become a pandemic and spread to over 195 
countries, with millions of cases and thousands of deaths worldwide. [1] Several ther-
apeutic agents were proposed, including antiviral agents (e.g. lopinavir-ritonavir, rem-
desivir), chloroquine/hydroxychloroquine, and Interleukin-6 pathway inhibitors. [2] 
Currently, there is a lack of definitive evidence of clinical benefits from these therapeutic 
agents. 
Corticosteroids were initially used in hospitalized patients with COVID-19 in China 
[3]; however, its use remains controversial as it may delay viral clearance and can cause 
complications. [4] Some experts advocate low-dose corticosteroid use in certain circum-
stances given the potential benefit of alleviating pulmonary fibrosis. [5] Convalescent 
plasma (CP) transfusion is another promising treatment for COVID-19 based on prior 
experiences treating Ebola, Middle East respiratory syndrome coronavirus, SARS-CoV1 
and H5N1. [6,7] CP transfusion has preliminary promising results against SARS-COV-2 
in 2 case series. [8,9] Clinical trials investigating the efficacy of CP are underway. This 
study aimed to share our clinical experience with corticosteroids and CP transfusion in 
five critically ill patients with COVID-19.
Methods
This study was conducted by the Infectious Diseases Department at Christus Spohn 
Hospital, Corpus Christi, Texas, USA, between March 23, 2020, and April 15, 2020. Food 
and Drug Administration (FDA) approval was obtained to use CP as an experimental 
therapy and as an emergency indication to treat severe COVID-19 infection. Following 
FDA approval, the Institutional review board (IRB) approved the study, and informed 
consent was obtained from the family to use CP. 
Patients were eligible for CP transfusion if they met the following criteria: a) severe 
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shortness of breath, respiratory rate > 30/mt, blood oxygen saturations <93%, Lung infiltrates >50%, multi-organ fail-
ure along with confirmed COVID-19 diagnosis using the qualitative reverse transcriptase-polymerase chain reaction 
(qRT-PCR) (LabCorp Laboratory) on nasopharyngeal secretions; b) bilateral lung infiltrates requiring invasive me-
chanical ventilation; and c) PaO2/FiO2 (P/F) ratio less than 100. 
Plasma donors were selected if they were previously diagnosed with laboratory-confirmed COVID-19 with complete 
resolution of the symptoms for fourteen days with negative result for COVID-19 on qRT-PCR. Appropriate type, screen, 
and cross-match were performed. Approximately 600 to 800 mL of convalescent plasma was retrieved from each do-
nor. The neutralizing activity of plasma against SARS-CoV-2 was not evaluated in our laboratory. It is assumed that 
derived plasma has enough antibodies with neutralizing activity. Following the donation, 250 to 400 ml of CP was given 
to all patients at least once. In addition to CP transfusion, these five patients received 5 days short course of corticoste-
roids, defined as methylprednisolone 40 mg intravenously every 12 hours for five days. Short course corticosteroids and 
plasma transfusion were given at different points of the patient’s disease course. Data are presented as actual values or 
mean (Standard deviations). Effect of short course corticosteroids and CP on P/F ratios and magnitude of change in P/F 
ratios after the treatment of short course corticosteroids and CP transfusion were summarized. Data were analyzed 
using SPSS v.24 (IBM, Armonk, NY).
Results
Five patients with severe COVID-19 infection who had severe hypoxemia (PaO2/FiO2 [P/F] <100) requiring invasive 
mechanical ventilation were admitted to ICU. All were male and with a mean age of 70 ± 9 years. All the patients had 
one or more co-morbidities. Demographics, co-morbidities, and medical treatments administered during hospitaliza-
tion are detailed in Table 1. All patients received short course methylprednisolone and CP transfusion. The volume of 
CP transfusion administered in our patients ranged from 250 ml to 400 ml. In the first two patients (patient A & B), 
CP transfusion was repeated three days after the initial transfusion. CP was started after short course corticosteroids, 
except in Patient E where short course corticosteroids and CP transfusion were given same day. These treatments and 
the starting day of the patient’s illness are summarized in Table 1. 
Methylprednisolone treatment preceded CP transfusion. The mean P/F ratio before short course corticosteroids was 
82 ± 14 and increased to 161 ± 53, three days after the treatment. Following CP transfusion, the mean P/F ratio improved 
from 139 ± 54 to 175 ± 65. The P/F ratios have increased by 46% and by 28% from finishing the treatment of short 
course corticosteroids and CP transfusions (Table 1). Trends of P/F ratio changes of all patients are shown in Figure 1. 
There were no significant side effects from methylprednisolone and CP transfusion during the hospital stay. 
The mean duration of invasive mechanical ventilation was 14 days (range: 4-22 days). Among these five patients, four 
survived and were successfully extubated within 7 days of starting short course corticosteroids and within five days 
after CP transfusion. One patient with significant co-morbidities died due to multi-organ failure from secondary infec-
tion.
Discussion
This case series delineated the clinical courses of five patients with severe COVID-19 on mechanical ventilation requir-
ing treatment of CP transfusion and short course corticosteroid treatment. Improved oxygenation indicated by the P/F 
ratio may be correlated with the methylprednisolone and CP transfusion. In our study, we have seen improvement in 
P/F ratios soon after starting steroids. Patients that started on steroids and CP transfusion earlier had a shorter venti-
lation course. 
Improved P/F ratios after CP treatment seen in this study was consistent with the results of two case-series studies. 
Shen et al. demonstrated that CP transfusion is associated with decreased viral loads and improvement in P/F ratios 
within 12 days in five patients. Unlike our study, they did not describe the timeline of steroids vs COVID-19 plasma 
administration, which could have skewed the results of oxygenation improvement, as the study did not differentiate 
between CP and steroids. [8] Similarly, Duan et al. also demonstrated clinical improvement and significant decrease in 
CRP level and viral loads and an increase in neutralizing antibody in ten patients. [9] The therapeutic effect from CP 
transfusion against COVID-19 is pathophysiologically plausible. The convalescent plasma collected from recovered 
patients from an infection contains antibodies that neutralizes the pathogen.   Passive transfer of these antibodies from 
plasma transfusion is hypothesized to prevent infection or reduce the severity of current infection through several 
mechanisms, including neutralization of infectivity via direct binding with pathogens, antibody-medicated comple-
ment activation, and antibody-dependent cellular cytotoxicity. [6,10]. These hypothetical effects were also observed in 
other infectious diseases (e.g. Ebola, SARS-CoV). [6,7] However, one should also note the potentially harmful effects 
associated with CP transfusion, including transfusion-related infection (e.g. hepatitis C virus) and transfusion-related 
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Table 1. Demographics, clinical characteristics and administered treatment of the patients.
Abbreviation: HTN = Hypertension, DM = Diabetes Mellitus, HIV = Human immunodeficiency virus, 
ESRD =End stage renal disease, CHF = congestive heart failure, CAD = Coronary artery disease
 Patients
 A B C D E
Demographics 
Age (years) 58 64 77 80 72
Gender  Male Male Male Male Male
Weight (kg) 119 105 80 109 102
BMI 37 31 29 33 30
Smoker  No No Ex-smoker No No






Mechanical Ventilation Day 2 Day 5 Day 1 Day 2 Day 1
Tocilizumab Day 7 Day 6 None Day 8 Day 1
Methylprednisolone Day 9 Day 13 Day 1 Day 6 Day 1
Plasma transfusion Day 12 Day 15 Day 3 Day 13 Day 1
Hydroxychloroquine with azithromycin Day 2 Day 2 Day 1 Day 5 Day 1
Vitamin C and Zinc Day 2 Day 2 Day 1 Day 5 Day 1
PaO2/FiO2
Before steroids 61 80 90 100 80
After steroids 90 130 180 180 228
Percentage change after steroids (%) 32 38 50 44 65
Before CP 64 170 180 180 100
After CP 81 150 190 200 256
Percentage change after CP (%) 21 -13 5 10 61
Survival No Yes Yes Yes Yes
reactions. The definitive role of CP transfusion in the management of COVID-19 disease is evolving.
Corticosteroid use in COVID-19 infection remains controversial. Concerns for delayed viral clearance and increased 
risk for complications from high-dose corticosteroids have led to WHO and CDC recommendations against its rou-
tine use in COVID-19. However, these suggestions were based on observational studies with potential selection bias 
and uncontrolled confounding that might obscure the clinical benefits of corticosteroids for a subset of patients with 
advanced acute respiratory distress syndrome (ARDS), such as attenuation of pulmonary fibrosis. [5] The expert panel 
from China recognized the potential benefits of short course corticosteroids and advocates for its use in COVID-19 
infections in certain settings. [7] The claimed benefits of short course corticosteroids were observed in our study. We 
observed a good response to short course corticosteroids, with improved oxygenation and close to 50% improvement in 
P/F ratio and a good survival rate of 80% (4/5) among elderly patients with various co-morbidities. 
There were several limitations of this study. First, since this was a small case series without controls, it prevented 
us from accurately ascertaining the definitive therapeutic benefits of short course corticosteroids and CP transfusion 
independently. Second, it was difficult to differentiate the therapeutic effect of CP transfusion from the remaining 
effects of short course corticosteroids given prior. Furthermore, it was not feasible to administer both a single agent 
and observe patients’ response before changing therapy in a critical setting. Third, the lack of evidence in both decreas-
ing viral loads and increasing neutralizing antibody titers after the short course corticosteroids and CP transfusion 
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Figure 1. The trend of changes of PaO2/FiO2 ratio after initiation of treatment of steroids and 
convalescent plasma transfusion.
A. Temporal changes in the P/F ratio of patients receiving steroids. Arrow represents the start 
date of treatment steroids. Patient A expired on day 10 post the initiation of steroids; patient 
C was extubated on day 8 post the initiation of steroids; patient E was extubated on day 6 
post the initiation of steroids. Patient E does not have a baseline PaO2/FiO2 ratio before the 
initiation of treatment of steroids.
B. Temporal changes in the P/F ratio of patients receiving convalescent plasma transfusion. 
Arrow represents the start date of the convalescent plasma (CP) transfusion. Patient A expired 
on day 10 post CP transfusion; patient B was extubated on day 8 post CP transfusion; patient 
C was extubated on day 6 post CP transfusion; patient D was extubated on day 8 post CP 
transfusion; patient E was extubated on day 6 post CP transfusion.
prevented us from confirming their efficacy. An additional limitation was lead-time bias, as the observed therapeutic 
effects could have resulted from patients’ self-recovery, as we have no controls for comparison. Furthermore, the time 
points of administered treatment differ across patients, which could be another source of heterogeneity. To understand 
better the timing for CP transfusion and its benefits in COVID-19 patients, we are planning a larger multicenter study 
with coordination of various centers in the USA.
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In summary, short course corticosteroids and convalescent plasma transfusion may improve oxygenation in patients 
with severe COVID-19 infections. Well-designed studies with adequate statistical power will shed more light on the 
benefits of short course corticosteroids and CP in patients with COVID-19 infections.
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